SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heightened social media activity as traders monitor its recent Xeon 6 integration into NVIDIAs next-generation AI infrastructure, fueling intense debates about the companys competitive position in the CPU market. While some investors remain bullish on Intel's long-term potential as a domestic foundry leader, others are frustrated by high volatility and rapid price reversals, leading to heated discussions about whether the stock is undergoing a genuine turnaround or merely experiencing unsustainable pump-and-dump cycles.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining market attention as investors weigh the recent Astria Therapeutics acquisition against high short interest and upcoming clinical data presentations at the AAAAI meeting. The community is actively debating the company's path to profitability and whether the pipeline progress, particularly regarding navenibart, will finally catalyze a significant breakout in share price.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing significant market interest following a series of strategic expansion announcements, including a major commitment to building autonomous vehicle charging infrastructure and new partnerships to integrate ride-hailing services. The community is actively debating the stock's long-term valuation versus its recent price volatility, with many investors highlighting substantial insider buying and institutional backing as signs of a potential bottom.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics is gaining significant market attention following a strategic equity offering that extends its cash runway and strengthens its balance sheet to support ongoing clinical milestones into 2027. Investors and community members are actively debating the impact of this capital raise, with many interpreting the participation of high-profile institutional entities as a vote of confidence in the company's proprietary radiopharmaceutical platform and its potential as a prime buyout target.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is trending following positive Phase 1 expansion data for its EpCAM-targeted ADC, Varsetatug Masetecan, in metastatic colorectal cancer, which spurred significant volume and bullish sentiment regarding its clinical pathway. The community is actively debating the stock's potential for a major buyout or partnership, weighing these promising clinical results against concerns over dilution and standard biotechnology sector volatility.

Semtech Corp. engages in the manufacture and supply of analog and mixed signal semiconductor products for high-end consumer, enterprise computing, communications, and industrial equipment. The firm operates through the following business segments: Protection, Signal Integrity, and Wireless & Sensing. It offers signal integrity, protection, wireless and sensing, and power and high-reliability products. The company was founded in 1960 and is headquartered in Camarillo, CA.

Semtech Corp.

Semtech is facing intense volatility as traders debate whether the recent sharp pullback is an overreaction or a fundamental shift, with community sentiment split between short-term short-sellers and those accumulating shares on the dip. The stock remains a major talking point as investors track institutional positioning, potential short-squeeze setups, and the company's broader exposure to AI-driven data center infrastructure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently driving market excitement as CEO Jensen Huang announced an aggressive revenue outlook during the annual GTC conference, projecting that demand for Blackwell and Vera Rubin systems will reach at least one trillion dollars by 2027. While some investors view these ambitious targets and expanded partnerships with firms like Uber and IBM as long-term validation of the company's AI dominance, others are wary of the stock's recent volatility and ongoing debate over the sustainability of capital expenditure in the AI infrastructure sector.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is facing significant selling pressure and volatility, fueled by concerns over ad revenue stability and broader market weakness, even as investors debate its potential as an AI-driven data asset. While some community members view the current price drop as a golden opportunity to accumulate shares, others remain skeptical, pointing to ongoing insider selling and sentiment erosion as reasons for caution.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid intense debate over the proposed Digital Asset Market Clarity Act, with the community split between bullish sentiment fueled by institutional partnership speculation and skepticism from those concerned about price manipulation. Traders are closely monitoring the token's correlation with broader market movements and its ability to maintain support levels as discussions around global adoption and potential regulation intensify.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is currently a focal point for investors as the community debates its valuation and potential for an acquisition or share buyback following a recent earnings report that sparked significant volatility. Traders are closely tracking the stock's performance relative to Uber, with intense discussions around the impact of autonomous vehicle partnerships and the company's long-term profitability metrics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Pharmaceutical Stocks To Keep An Eye On - March 16th

Eli Lilly and Company, CytomX Therapeutics, Pfizer, HCW Biologics, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks...

Best Medical Stocks To Watch Today - March 16th

Eli Lilly and Company, CytomX Therapeutics, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price?

Key PointsEli Lilly's growth rate has accelerated significantly in recent years due to its GLP-1 drugs...

Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial

Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.read more...

Hilltop Holdings Inc. Acquires 8,154 Shares of Eli Lilly and Company $LLY

Hilltop Holdings Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 97.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The...

Holocene Advisors LP Has $114.14 Million Stock Position in Eli Lilly and Company $LLY

Holocene Advisors LP decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 78.0% during the 3rd quarter, according to the company in its most recent 13F filing with...

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic...

ICONIQ Capital LLC Cuts Position in Eli Lilly and Company $LLY

ICONIQ Capital LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 90.4% during the third quarter, according to the company in its most recent filing with the Securities...

Fred Alger Management LLC Has $73.09 Million Stock Holdings in Eli Lilly and Company $LLY

Fred Alger Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 39.2% during the third quarter, according to its most recent Form 13F filing with the...

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Current Price	$989.12
Prev Close	$985.08
Open	$991.98
Dividend Yield	0.56%
50-Day Moving Average	$1,038.87
Beta	0.68
Avg. Volume	3.82M
PE Ratio	43.61

52-Week High	$1,133.95
52-Week Low	$623.78
Market Capitalization	$931.18B
EPS (Annual)	$22.95
Price to Book	35.07
Revenue Per Employee	$1.3M

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LLY News

LLYLilly(Eli) & Co